María Jesús
Garrido Cid
Catedrática de Universidad
Centro de Investigación Médica Aplicada
Pamplona, EspañaPublicacións en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (9)
2022
-
Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria
Science Translational Medicine, Vol. 14, Núm. 627
2021
-
Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model
Journal of Nanobiotechnology, Vol. 19, Núm. 1
-
Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1
British Journal of Cancer, Vol. 124, Núm. 7, pp. 1275-1285
-
Semi-mechanistic model for the antitumor response of a combination cocktail of immuno-modulators in non-inflamed (Cold) tumors
Cancers, Vol. 13, Núm. 20
2019
-
A new immune-nanoplatform for promoting adaptive antitumor immune response
Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 17, pp. 13-25
2017
-
Commentary on Pharmacometrics for Immunotherapy
CPT: Pharmacometrics and Systems Pharmacology, Vol. 6, Núm. 1, pp. 8-10
2010
-
A semi-physiological-based pharmacokinetic/pharmacodynamic model to describe the effects of topotecan on B-lymphocyte lineage cells
Pharmaceutical Research, Vol. 27, Núm. 3, pp. 431-441
2008
-
Characterization of cisplatin cytotoxicity delivered from PLGA-systems
European Journal of Pharmaceutics and Biopharmaceutics, Vol. 68, Núm. 3, pp. 503-512
-
Semi-mechanistic description of the in-vitro antiproliferative effect of different antitumour agents
Journal of Pharmacy and Pharmacology, Vol. 60, Núm. 1, pp. 77-82